Selecta attracts $15 million more in venture funds

04/5/2010 | Boston Globe (tiered subscription model), The

Massachusetts-based Selecta Biosciences, which builds nanotechnology structures for vaccines, has raised $15 million in new venture capital. The nanoparticles Selecta creates can trigger an immune response, which has the potential to "leapfrog biological vaccines," said Selecta's Executive Chairman Robert L. Bratzler.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief: